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ABSTRACT:
Multiple systems have been affected by COVID-19 infection, and neurological symptoms are not uncommon. A
45-year-old male presented to us in the emergency department without focal neurological deficits. He developed
ascending paralysis soon after his admission, which was followed by worsening respiratory symptoms. The family of the
patient refused a lumbar puncture, and his NCS/EMG showed features of acute motor axonal neuropathy (AMAN), a
variant of Guillain-Barré syndrome (GBS). After being admitted on the 4th day, the patient developed type 2 respiratory
failure and died on the 5th day of admission before any treatment could be started. Patients with COVID-19 may
worsen their respiratory compromise due to a rare yet treatable neurological disease that should be addressed
immediately to prevent complications and death.
INTRODUCTION
Globally, more than 100 million cases of SARS-CoV-2
infections have been reported so far with just under 2
million deaths since the outbreak in the Chinese city of
Wuhan in December of this year(1). The evidence also
indicates that it may lead to neurological diseases (2).
These include headaches, anosmia, and ageusia (3). In
214 hospitalized patients infected with SARS-CoV-2 in
Wuhan, China, neurological symptoms were assessed.
36.4% of those 214 patients had a neurological
manifestation such as headache, hyposmia,
hypogeusia, muscle damage, dizziness, hemorrhagic
and ischemic stroke (4). GBS is an immune-mediated
disease wherein peripheral nerves and nerve roots are
affected (polyradiculoneuropathy), and the disease is
often preceded by various viral or bacterial infections (5).
A symmetrical, progressive, ascending flaccid limb
paralysis is usually associated with areflexia or
hyporeflexia. Cranial nerve involvement may or may not
be present. The disease usually progresses over a
period of several weeks (5) followed by a plateau and a
recovery phase. GBS symptoms usually appear two to
four weeks before gastrointestinal or respiratory
infections are prevalent in 60 to 70% of patients (6). This
is a rare case of COVID-19 infection that later
manifested as GBS.

a temperature of 103.5F, a pulse of 112 beats per
minute, a blood pressure of 110/65mm of Hg, and a
respiratory rate of 32 breaths per minute. On room air,
the patient had a saturation of 73% on a pulse
oximeter and was severely short of breath at
presentation. The chest auscultation revealed coarse
crackles bilaterally. During the time of presentation, his
neurological examination was normal, and he was
following commands. After HRCT Chest (Figure-1) and
positive RT-PCR for SARS-CoV-2, he was admitted to an
isolation ward for treatment of severe COVID-19
Pneumonia and was given high flow oxygen,
tocilizumab, and remdisivir along with symptomatic
management.
After the third day of admission, the patient developed
weakness in his lower limbs ascending. The power in
the lower limb was 1/5 distally and 3/5 proximally. In
addition to decreased tone, his lower limb reflexes were
absent, and his upper limb reflexes were depressed.
Planters were mute on both sides and sensations were
normal throughout. A lumbar puncture was not
performed due to the patient's clinical condition. The
next day, the patient's weakness progressed to the
upper limbs, and power was noted to be 2/5 distally in
the hands and 4/5 proximally. Immediately, nerve
conduction studies were performed which showed
decreased amplitudes with slight reductions in
conduction velocities (Figure-2) in multiple nerves both
in the upper and lower limbs while his EMG
demonstrated neuropathic changes in all muscles
sampled.

CASE PRESENTATION
A 45-year-old male presented to us with a five-day
history of high-grade fever, cough, body aches, fatigue,
and shortness of breath. With the exception of 10
pack-years of smoking, he had no previously known
co-morbidities. In the emergency room, the patient had
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Patient was diagnosed with Guillain-Barré syndrome and
given the treatment options of intravenous
immunoglobulin and plasmapheresis. Patient condition
worsened on day 4 of admission, and he developed type
2 respiratory failure. On the following day, he died at
COVID-19 ICU.

Figure-2: NCS findings.

Figure-1: HRCT chest; Axial image showing dense
peripheral based patches of consolidations with air
bronchogram and few small peripheral ground glass
opacities.
Table 1:

DISCUSSION:
GBS usually manifests itself over a period of a few days
to 6 weeks and is usually preceded by respiratory or
gastrointestinal infections (7). There have been numerous
reports of its association with viral infections, such as
HIV, EBV, and most recently Zika virus (7,8). In most cases,
it is thought to be due to an autoimmune response where
antibodies are developed against the glycoprotein found
on the surface of the causative organisms, which is
similar to a similar protein found on peripheral nerves,
resulting in neurological damage (7). SARS-CoV-2 caused
a similar reaction in our patient, resulting in GBS. The
subcontinent has not yet reported any cases of GBS
caused by SARS-CoV-2. To date, only one case series (9)
and two case reports (10,11) have been documented
worldwide.
Our case presented all the characteristics of a typical,
but severe GBS. During the current infection, the patient
developed a full-blown case of GBS that started out as a
normal neuropathy. Because of the general condition of
patients with severe SARS-COV-2 infection, neurological
symptoms like those in our patient can be easily missed.
As a result, physicians should pay careful attention to
peripheral neuropathies and seek neurological
consultation whenever such symptoms are observed in
patients with SARS-CoV-2 infection.

admission also indicated an acute infection. In this case,
GBS shows a para-infectious pattern, rather than the
usual post-infectious pathology in respiratory or
gastrointestinal infections. Such an association may
merit further study and may require further
epidemiological data.
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As a rather novel virus, SARS-CoV-2 requires further
study in order to understand its virulence and
pathogenicity. Neurological complications like in our
patient should be aggressively treated if possible, to
prevent further respiratory compromise. Initially, our
patient presented with symptoms of SARS-CoV-2
infection, but soon developed classic GBS symptoms.
His initial and follow-up investigations on the third day of
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CONCLUSION:
There is an association between SARS-CoV-2 infection
and a neurological disease in this case report. This may
cause rapid deterioration and even death. Clinicians are
urged to keep an eye out for symptoms related to
SARS-COV-2 that can easily be missed. Comprehensive
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